BIODESIX INC

Biodesix, Inc. is a diagnostic solutions company focused on transforming patient care and improving outcomes through personalized diagnostics, primarily in lung disease. The company operates in the diagnostic testing industry, leveraging multiple technologies including genomics, proteomics, and radiomics, combined with artificial intelligence (AI), to discover, develop, and commercialize innovative diagnostic tests. The company's mission is to conquer patient disease through personalized diagnostics, and it envisions a world where timely and accessible diagnostics address immediate clinical needs. The lung cancer continuum of care in the United States represents over 10 million annual testing opportunities and a market opportunity greater than $27 billion annually ¹.

The company's core business model revolves around two primary revenue sources: Biodesix Lung Diagnostic Testing and Biodesix Development Services. Lung Diagnostic Testing provides blood-based testing services for healthcare providers, while Development Services offers diagnostic testing and consulting to biopharmaceutical, life sciences, and diagnostic companies. Revenue generation is a mix of transactional income from tests delivered and contract-based income from development services. Primary customer segments include healthcare providers (pulmonologists, primary care physicians), biopharmaceutical companies, life sciences companies, and academic research institutions. The company emphasizes a multi-omic and collaborative approach to solving diagnostic challenges, integrating new technologies into its evolving offering.

Biodesix Lung Diagnostic Testing includes five blood-based tests that support clinical decisions for patients with lung disease. Two tests, Nodify CDT® and Nodify XL2®, are marketed as Nodify Lung® Nodule Risk Assessment, which classify a patient's risk of lung cancer in suspicious lung nodules. The Nodify CDT test identifies patients with a higher risk of malignancy by measuring seven circulating autoantibodies (P53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD, and MAGE A4) ² and has an average turnaround time of one business day ³. The Nodify XL2 test identifies patients with a reduced risk of cancer by measuring two peptides (LG3BP and C163A) ⁴ and integrates clinical and radiological characteristics, with results typically available within four to five business days ⁵. The other three tests, VeriStrat®, GeneStrat® ddPCR, and GeneStrat NGS®, are marketed as part of the IQLung® testing strategy, providing treatment guidance after a lung cancer diagnosis. The VeriStrat test is a blood-based proteomic test that profiles the patient's immune system by measuring eight protein features ⁶ to inform physicians about cancer aggressiveness and treatment planning, with an average turnaround time of three business days ⁷. The GeneStrat ddPCR test detects guideline-recommended actionable mutations (EGFR, KRAS, BRAF, EML4-ALK, ROS-1, and RET) ⁸ and has an average turnaround time of two business days ⁹. The GeneStrat NGS test is a blood-based 52-gene tumor profiling test panel ¹⁰ for late-stage, metastatic NSCLC, also with an average turnaround time of three business days ¹¹.

Biodesix Development Services enables biopharmaceutical, life sciences, and academic research institutions with scientific, technological, and operational capabilities. These services include translational research, biomarker discovery, assay design, development, validation, clinical trial sample testing, regulatory support, reimbursement, commercialization, and logistical support. The company offers its existing on-market tests, other research tests, and the capability to custom design novel tests for customers. This segment has been utilized by over 65 industry clients and academic research partners ¹².

For the fiscal year ended December 31, 2025, Biodesix reported total revenue of $88.499 million ¹³, an increase of 24% ¹⁴ over 2024. Gross margin percentage improved to 81% ¹⁵ from 78% in 2024 ¹⁶. Operating expenses totaled $116.372 million ¹⁷, leading to a loss from operations of $27.873 million ¹⁸. Net loss for the year was $35.265 million ¹⁹, an 18% ²⁰ improvement compared to a net loss of $42.931 million ²¹ in 2024. Basic and diluted EPS are not explicitly stated, but the net loss per share can be inferred from the net loss and shares outstanding. Cash and cash equivalents were $19.0 million ²² as of December 31, 2025, including $2.3 million ²³ in at-the-market proceeds. Total borrowings and interest obligations were $62.335 million ²⁴ as of December 31, 2025.

Year-over-year, total revenue increased by $17.176 million ²⁵, or 24% ²⁶. Lung Diagnostic Testing revenue grew by $14.489 million ²⁷, or 22% ²⁸, reaching $79.197 million ²⁹ in 2025, driven by a 15% ³⁰ increase in tests delivered to 62,600 ³¹ and improvements in average revenue per test. Development Services revenue increased by $2.687 million ³², or 41% ³³, to $9.302 million ³⁴. Direct costs and expenses increased by $1.146 million ³⁵, or 7% ³⁶, to $16.719 million ³⁷, primarily due to increased testing volume, partially offset by workflow optimization. Research and development expenses increased by $2.442 million ³⁸, or 26% ³⁹, to $12.001 million ⁴⁰, driven by increased headcount and variable compensation, as well as higher external clinical trial costs. Sales, marketing, general and administrative expenses increased by $7.094 million ⁴¹, or 9% ⁴², to $87.545 million ⁴³.

Significant operational developments during 2025 included the enrollment of over 1,500 patients ⁴⁴ in the CLARIFY study, which aims to collect patient outcomes and clinical information on 4,000 patients ⁴⁵ who received Nodify Lung® Nodule Risk Assessment testing. The ALTITUDE clinical utility study ended patient accrual on July 21, 2025 ⁴⁶, with final analysis to be completed after two-year follow-up. The INSIGHT observational study completed enrollment of 5,000 patients ⁴⁷ on June 27, 2023, with final analysis estimated by the end of 2026 ⁴⁸. The company also announced an expanded partnership agreement in October 2025 ⁴⁹ to develop, clinically validate, and submit regulatory applications for in vitro diagnostic (IVD) assays, including Bio-Rad’s ddPLEX ESR1 Mutation Detection Assay, utilizing Bio-Rad’s Droplet Digital™ PCR (ddPCR™) technology on Bio-Rad’s QX600 platform. In March 2024, a new master collaborative research agreement was announced with Memorial Sloan Kettering Cancer Center (MSKCC) ⁵⁰ to collaborate on diagnostic tests for cancer treatment improvement, including molecular residual disease (MRD). The company also effected a 1-for-20 reverse stock split on September 15, 2025 ⁵¹ to regain compliance with Nasdaq's minimum bid price requirement.

Management expects continued operating leverage as its expanded sales team advances along the productivity curve and converts growing experience into sustained performance. The company expects its investments in research and development to increase, and further expects to increase its research and development expenses to fund further innovation and develop new clinically relevant tests. As services revenue grows, an increasing portion of research and development dollars are expected to be allocated to cost of services for biopharmaceutical service contracts. This expense, though expected to increase in dollars, is expected to decrease as a percentage of revenue in the long term, though it may fluctuate as a percentage of revenues from period to period due to the timing and extent of these expenses. The company also plans to increase its sales and marketing expenses in dollars as it expands its sales force, increases its presence within the United States, and increases its marketing activities to drive further awareness and adoption of its tests and future products and services. These expenses, though expected to increase in dollars, are expected to decrease as a percentage of revenue in the long term, though they may fluctuate as a percentage from period to period due to the timing and nature of these expenses. General and administrative expenses are expected to continue to increase in dollars, primarily due to increased headcount and costs associated with operating as a public company, including expenses related to legal, accounting, regulatory, maintaining compliance with exchange listing and requirements of the SEC, director and officer insurance premiums and investor relations. These expenses, though expected to increase in dollars, are expected to decrease as a percentage of revenue in the long term, though they may fluctuate as a percentage from period to period due to the timing and extent of these expenses.

A major growth area for Biodesix is the continued expansion of its Lung Diagnostic Tests. The company's strategy involves driving increased awareness, adoption, and reimbursement coverage of its diagnostic tests. This includes continuously educating healthcare providers, key opinion leaders, hospital systems, advocacy groups, patients, payers, academic research organizations, and technology assessment and guideline organizations on the clinical data and benefits of its tests. The company plans to continue investing in the expansion and professional development of its lung-focused clinical sales force and commercial support teams, and extending its commercial reach in clinics specializing in lung nodule management and lung disease diagnosis, as well as their primary care referral networks. Furthermore, Biodesix will invest in clinical studies and publish additional clinical data to increase market adoption and reimbursement coverage, publish health economics and outcomes research demonstrating the impact of its tests on the US healthcare system and decreasing overall costs, and engage key opinion leaders and partners to identify existing or emerging clinical needs in lung disease to develop new tests.

Another significant growth area is the expansion of Biodesix Development Services. The company aims to expand revenue-generating contracts with research institutions, biopharmaceutical clients, and life sciences customers. This will be achieved by leveraging its team's expertise and multi-omic offering to sell a comprehensive line of research, discovery, development, clinical trial testing, regulatory, reimbursement, commercialization, and logistics support services across cancer types and diseases. The strategy also includes adding new biopharmaceutical, life science, tools, and diagnostic customers, and leveraging existing projects and relationships to expand engagement with current customers. The company will engage with customers, key opinion leaders, leading academic centers, and scientific experts to stay ahead of the rapidly evolving diagnostic and therapeutic landscape and to identify unmet clinical needs. Strategic partnerships with biopharmaceutical companies, academic research organizations, technology providers, and other diagnostic companies are also a part of this growth strategy.

Operationally, the company expects the aggregate cost of diagnostic testing to increase in line with the increase in the number of tests performed, but the cost per test is expected to decrease modestly over time due to efficiencies gained from increased test volume, automation, and other cost reductions. The company's pipeline strategy leverages existing infrastructure, both personnel and technology, to support Lung Diagnostic Tests and Development Services workstreams, creating a cost-effective development funnel. This includes internal projects focused on improvements to existing diagnostic tests and external collaborations with academic partners for new test development and exploring additional clinical utility for the existing portfolio.

Planned capital allocation includes continued investment in research and development, particularly in clinical studies for on-market and pipeline products to support expanded payer coverage, commercial adoption, and regulatory approvals. The company raised approximately $7.3 million ⁵² in gross proceeds from the sale of 892,841 ⁵³ common shares at a weighted average price per share of $8.20 ⁵⁴ under its 2024 ATM Program during 2025, with $42.7 million ⁵⁵ remaining available capacity. Subsequent to December 31, 2025, the company raised an additional $14.7 million ⁵⁶ in ATM proceeds. The Senior Secured Term Loan with Perceptive Advisors was amended subsequent to the end of the quarter to extend the maturity date and interest-only period to November 2028 ⁵⁷. The company has never declared or paid dividends on its common stock and does not expect to pay dividends for the foreseeable future, anticipating that all liquidity will be used for the operation and growth of its business.

Management explicitly flagged several structural headwinds and execution risks to its growth plan. The commercial success and revenue growth are highly dependent on the demand for, and increased adoption of, its diagnostic tests, which are subject to risks and uncertainty. The company needs to ensure strong product performance and reliability to maintain and grow its business, as poor performance could lead to customer dissatisfaction and increased costs. Dependence on third-party suppliers, including single-source suppliers like Bio-Rad for the GeneStrat test and Freenome for the Nodify CDT tests, makes the company vulnerable to supply problems and price fluctuations. While second source qualification is underway for critical components, success is not guaranteed. The company may not be able to sufficiently reduce costs in the performance, manufacturing, and production of its diagnostic tests to achieve sustainable gross margins. Natural or man-made disasters and other similar events could significantly disrupt business operations, particularly given the centralization of facilities in Louisville, Colorado, and De Soto, Kansas. The industry is subject to rapid change, and failure to continuously innovate and improve diagnostic tests could lead to loss of customers or market share. Any failure to offer high-quality support for diagnostic tests and services may adversely affect relationships with providers and negatively impact reputation.

Geographic, regulatory, and macro factors identified as constraints include the uncertainty surrounding the insurance coverage and reimbursement status of newly approved diagnostic tests, particularly in a new category of diagnostics and therapeutics. Changes in the reimbursement landscape, including potential impacts from the "Consolidated Appropriations Act, 2026" ⁵⁸ if enacted, could affect payment rates for certain tests. Healthcare reform measures could hinder or prevent commercial success, increasing costs or subjecting the company to additional regulatory requirements. The company is subject to extensive federal, state, local, and foreign environmental, health, and safety laws and regulations, and permitting and licensing requirements. Compliance with anti-corruption, anti-bribery, anti-money laundering, and similar laws, including the FCPA, is critical, especially with international operations through third-party partnerships. The use, disclosure, and processing of personally identifiable information, including health information, is subject to HIPAA and other federal, state, and foreign privacy and security regulations like GDPR, with non-compliance potentially leading to significant liability or reputational harm. Cybersecurity risks, including cyber-attacks and data breaches, pose a continuous threat to systems and data, requiring significant resources for protection and mitigation. Artificial intelligence introduces emerging risks and challenges, including competition and evolving regulatory landscapes.

The company faces material macroeconomic risks, including global economic and financial market conditions susceptible to significant stresses, which could lead to reductions in available credit, government spending, economic downturns, foreign currency fluctuations, and volatility in securities valuations. Enhanced U.S. tariffs, import/export restrictions, or other trade barriers, particularly those imposed by the U.S. presidential administration, may negatively impact global economic conditions, financial markets, and the company's business. Operationally, the company has a history of net losses, reporting $35.3 million ¹⁹ in 2025 and $42.9 million ²¹ in 2024, and expects to continue incurring losses, making sustained profitability uncertain. Significant payer concentration is a risk, with Medicare reimbursing 32% ⁵⁹ of total revenue in 2025 and 39% ⁶⁰ in 2024, making the company vulnerable to changes in reimbursement policies or termination of relationships with large payers. Dependence on third-party suppliers, including single-source providers for critical components like Bio-Rad for the GeneStrat test and Freenome for the Nodify CDT tests, exposes the company to supply problems and price fluctuations. The company's facilities in Louisville, Colorado, and De Soto, Kansas, are susceptible to natural or man-made disasters, which could disrupt operations. Regulatory risks are substantial, particularly regarding the evolving landscape of FDA regulation of Laboratory Developed Tests (LDTs); while a U.S. District Court vacated the FDA's final rule to actively regulate LDTs on March 31, 2025 ⁶¹, future legislative or administrative actions could still subject the company's tests to pre-market review, incurring substantial costs and delays. Compliance with federal and state healthcare fraud and abuse laws, such as the Anti-Kickback Statute and False Claims Act, and international anti-corruption laws like the FCPA, is critical, with violations potentially leading to significant civil, criminal, and administrative penalties. Data privacy and security laws, including HIPAA and GDPR, impose strict requirements on handling personal health information, and any breaches could result in significant liability or reputational harm. The company's Perceptive Term Loan Facility of $50.0 million ⁶² contains covenants, including a minimum cash requirement and a trailing twelve-month net revenue requirement, with failure to comply potentially leading to an event of default and acceleration of debt.

Management's overall tone emphasizes a commitment to transforming patient care through personalized diagnostics, highlighting the company's deep experience in diagnostics and a multi-omic approach leveraging genomics, proteomics, and AI. They stress the importance of establishing a new standard of care through extensive understanding of clinical needs, scientific expertise, clinical evidence development, scalable operational infrastructure, and an established commercial channel. Management reported estimated total revenue of $88.5 million ¹³ for 2025, a 24% ¹⁴ increase over 2024, with Lung Diagnostic Testing revenue at $79.2 million ²⁹ (up 22% ²⁸) and Development Services revenue at $9.3 million ³⁴ (up 41% ³³). Gross margin percentage improved to 81% ¹⁵ from 78% ¹⁶ in 2024. Key strategic priorities for the period ahead include driving increased awareness, adoption, and reimbursement coverage of their Lung Diagnostic Tests through continuous education, sales force expansion, and investment in clinical studies and health economics research. A second priority is expanding revenue-generating contracts with biopharmaceutical, life sciences, and academic research customers by leveraging their multi-omic offering and expertise. Finally, management is focused on pipeline development, including new tests for lung disease and collaborations for pan-cancer applications like molecular residual disease (MRD) and expanded use of the VeriStrat test in other cancers, while also ensuring operational efficiencies and cost discipline, as evidenced by limiting operating expense growth (excluding direct costs and expenses) to 10% ⁶³ over 2024.